$CRCL | Circle Internet Q2’25 Summary • Revenue: $658M 🟢 (Est. $644.7M) | +53% YoY • EPS: -$0.18 🔴 (Est. $0.34) → non-cash expenses, largely driven by the IPO; Net Loss -$482M (including $591M IPO-related charges) USDC & Operations • USDC in circulation: $61.3B (+90% YoY) — Aug 10: $65.2B • Avg USDC: $61.0B (+86% YoY) • Market share: 28% (+595 bps YoY) • USDC on platform: $6.0B (+924% YoY) • Meaningful wallets: 5.7M (+68% YoY) Profitability • Adj. EBITDA: $126M (+52% YoY), margin 50% (+463 bps) 🟢 • RLDC: $251M (+38% YoY); margin 38% (-408 bps) → to watch Guidance • USDC growth: ~40% CAGR (multi-year) • FY25 Other Rev: $75–85M | FY25 RLDC margin: 36–38% • FY25 Adj. Opex: $475–490M Strategy / Corporate • $1.2B IPO completed; $583M net cash • Circle Payments Network (May): 100+ institution pipeline • Arc: L1 for stablecoin finance (public testnet fall) • Partnerships: Binance, Corpay, FIS, Fiserv, OKX • GENIUS Act enacted → Federal stablecoin framework in the US CEO – Jeremy Allaire: IPO marks critical turning point for Circle and stablecoin adoption; cross-industry interest accelerates. My comment: Strong outlook: USDC volume & market share accelerating; core profitability (Adj. EBITDA, 50% margin) healthy. Red dot: EPS/Net loss largely a non-cash accounting impact from the IPO; not a sign of operational weakness. 3 key points in focus: (1) Is USDC circulation growth sustainable? (2) Is the RLDC margin reversing from 38%? (3) Actual adoption/integration speed in Payments Network & Arc. Thesis: Regulation clarified with the GENIUS Act + institutional partnerships → Increases revenue visibility in 2H25. Risks: Crypto volume cycle, Tether competition, maintaining OPEX discipline. Not investment advice!!! #CRCL #USDC #Stablecoin #Crypto #Fintech #Earnings #Web3 #Payments #Blockchain

📊 MAG7 vs. S&P 493 – April 7 → August 12, 2025 The market picture is clear: The big ones are carrying, the broad base is providing limited support. Here's an X-ray of the last 4.5 months ⬇️ 🔹 MAG7 (AAPL, AMZN, GOOGL, META, MSFT, NVDA, TSLA) • Index Weight: ~35.4% 📈 (record high) • Performance: +10.7% • Earnings growth +28% in Q1, continued strong in Q2 • Still priced in with the "AI + quality growth" narrative • Risk: High valuation → susceptibility to surprises 🔹 S&P 493 (Remainder) • Performance: +4.1% (RSP index) • Breadth: 55% at 200-day moving average • Earnings growth, but above-index momentum is limited • Valuation is more reasonable → potential for "catch-up" 🔹 Overall Index (S&P 500) • Performance: +8.3% • P/E: 22.1x → Above 5- and 10-year moving averages • Q2 earnings growth: 11.8% (mega-caps again the driving force) 📌 Reading: While the MAG7 rebounded ~35% from its April 7 lows, the broad base remains moderate. Most of the index's rise comes from giants. Concentration risk is high → the impact is disproportionate, both in the uptrend and downtrend. 📌 Tactical Recommendation: - Strengthen the Majors: Include companies with growing profits and strong balance sheets (excess cash) within the MAG7 in your main portfolio. - Layer the Rest: Add small-medium weightings to sectors (healthcare, select industrials, some defensive stocks) within the 493 whose earnings expectations have been revised upwards and whose prices remain reasonable. - Divide Risk: Don't concentrate your investment solely on giant stocks; Diversify with products like the equal-weight index (RSP) or the S&P 500 – Excluding Top 10 Stocks. - Follow the Macro: Fed interest rate decisions, inflation data, and global trade news can quickly change the direction of mega-cap stocks in particular. This is not investment advice, but for informational purposes only!!! #MAG7 #SP500 #Finance #StockMarket #Investment #Stocks #MarketAnalysis #Investor #BorsaIstanbul #NASDAQ #WallStreet #Economy #FinancialLiteracy #Index #InvestmentStrategy #Portfolio

As the rally in technology stocks boosts market sentiment, investors continue to assess the impact of Trump's new tariffs. 🔹 S&P 500 futures: +0.3% 🔹 Nasdaq 100 futures: +0.3% 🔹 Dow futures: +0.2% 📊 Bond Market 10Y return: 4.26% (flat) 2Y return: +1bp ➡ 3.75% 📌 Thursday Summary S&P 500: -0.08% (Eli Lilly earnings pressured) Nasdaq: +0.35% 🆙 Mag-7: +0.40% 📈 (All-time high) 💬 Deutsche Bank – Jim Reid: “Trump’s chip tax exemptions and the easing of Russia-Ukraine tensions have tempered optimism. Tariffs have taken effect, but the market reaction has been weak.” 📰 Other Developments Trump tariffs officially began last night Fed Governor Waller is emerging as a candidate for chairman after Powell Today's data agenda is quiet; St. Louis Fed President Musalem will speak #SP500 #Nasdaq #DowJones #TrumpTariffs #BondMarket #Fed #Markets

$RXRX Analysts Confident in Recursion Pharmaceuticals' Future: Earnings Estimates Rising! 📈 Biotechnology company Recursion is on analysts' radars. The company's revenue is expected to jump from approximately $70.58 million this year to $113.91 million next year, a growth of over 61%. This strong growth outlook has analysts painting an optimistic outlook for the stock. The 25% revenue surpassing expectations in the last quarter was a major driver of this positive sentiment. Partnerships with industry giants like Sanofi, including a potential $300 million payout, also bolster confidence in the company's future revenue streams. The consensus rating from five analysts is "Buy," while the average price target for the stock is $7.00. This target suggests a potential upside of approximately 29% from the current price. The fact that the company has sufficient cash reserves until the last quarter of 2027 also demonstrates its financial resilience.

📊 $CELH | Celsius Holdings Q2 25 Earnings 🔥 🚀 Revenue: $739.3M (Considered: $654.3M) 🟢 +84% YoY 💵 EPS (Adjusted): $0.47 (Considered: $0.24) 🟢 +68% YoY 📦 EBITDA: $210.3M ➕ +109% YoY 📈 US Ready-to-Energy Drink Market Share: 17.3% (+180bps) ▫️ CELSIUS: 11% (-130bps) ▫️ Alani Nu: 6.3% (+310bps) 🛒 Retail Sales Growth (YoY): ▫️ CELSIUS: +3% ▫️ Alani Nu: +129% ▫️ Total Portfolio: +29% 🌎 Revenue Breakdown: ▫️ North America: $714.5M (+87%) ▫️ International: $24.8M (+27%) 🎯 CEO: We're shaping the category with Celsius and Alani Nu. Sugar-free, functional energy is our responsibility! #CELH #Earnings #Celsius #AlaniNu #EnergyDrink #BalanceSheet #FinancialData #Investment

🎮 $U | Unity Q2 2025 Earnings Summary 🔹 Revenue: $440.9M (expected $426.7M) ✅ → However, -2% YoY contraction 🔹 Adj. EPS: $0.18 (expected -$0.28) ✅ 📊 Q2 Segment Details: 🔸 Create Solutions: $154M (+2% YoY) 🔸 Grow Solutions: $287M (-4% YoY) 🔸 Unity Ad Network: +15% QoQ → 49% of the Grow segment 📈 Q3 Guidance: 🔹 Revenue: $440M–$450M (expected $445.1M) ➖ 🔹 Adj. EBITDA: $90M–$95M 🔹 "Grow" segment: Mid-single-digit quarterly growth expected 🔹 "Create" segment: Slight contraction expected 💰 Operational Data: 🔹 Adj. EBITDA: $90M (21% margin) 🔹 Free Cash Flow: $127M (previously $80M) 🔹 Net Operating Cash: $133M (previously $88M) 🔹 Cash & Cash Equivalents: $1.70B ($1.53B in December 2024) 🗣️ CEO Matt Bromberg: This quarter is a turning point for Unity. Our Unity Vector strategy is reshaping our growth potential. We surpassed the upper bounds in both revenue and EBITDA. 📌 Comment: Unity delivered a strong positive surprise in EPS and EBITDA, but annual revenue remains negative. The growth side is declining, but the ad network's recovery is positive. The create side is experiencing stable but limited growth. There is a significant improvement in cash flow, and the balance sheet is becoming more resilient. 🔸 The "Unity Vector" strategy may herald a transformation. 🔸 Limited growth in the short term, with a more aggressive recovery possible in the medium term. 🔸 Margins are strong, and operational efficiency is improving. Unity is still in transition, but signs of a bottoming out are becoming clear. #Unity #U #Earnings #GameDev #AdTech #Q22025 #TechStocks #TradersPub #Investment #BalanceSheetAnalysis

Oscar ($OSCR), like its competitors, has been negatively impacted by the rise in the US morbidity rate. Morbidity refers to the average health deterioration in the US population. While the exact cause is unknown, Americans are now less healthy. The impact is reflected in the "Medical loss ratio" line on the income statement. This means the company is now paying more premiums back to policyholders as claims. I thought morbidity could be a problem, but Oscar could manage it with artificial intelligence applications. It seems I was wrong, at least for now. I was predicting OSCR could better select and price patients with AI, but that's been a lie for now. 📈 Oscar Health 2025 Q2 Results Announced! 📉 Oscar Health announced its Q2 2025 financial results. While revenue and EPS fell short of expectations, the company maintained its year-end revenue guidance. Here are the details: 🔹 Revenue: 2.86 Billion (Expected 2.92 Billion) 🔴 🔹 Earnings per Share (EPS): -0.89 (Expected -0.84) 🔴 🔹 Memberships: 2.03 Million (+29% YoY increase) Annual revenue guidance remained unchanged at 12.0 Billion - 12.2 Billion. The company stated that it experienced a loss in the quarter due to increased risk adjustment costs in the insurance market. CEO Mark Bertolini: "We believe the individual market has long-term potential and that the future is in healthcare." #OscarHealth #OSCR #Finance #StockMarket #Technology #Healthcare #Investment #Economy

Novo Nordisk's Q2 earnings report fell short of expectations, but sales of its weight-loss drug Wegovy were impressive! 🟢 However, due to competition and slowing GLP-1 growth, the company lowered its full-year guidance and is considering a CEO change. 📉 #NovoNordisk #NVO #StockMarket #Finance #Wegovy #Ozempic #EarningsReport

📉 Unfortunately, a lackluster earnings report for AMD. I was afraid of weak EPS, and it came true. At least there are positive signals on the forward guidance side. However, when expectations are set high, high price volatility is inevitable. If we hold above $170, perhaps even close the week above this level, we will have survived with minimal damage. The market loves to exaggerate. Conversely, if a correction is possible, a dip to $140-$150 could be a buying opportunity for those looking to add to their portfolio. 📢 Here are my key points: • Q3 guidance does not include the MI308 revenues planned for sale to China. The sale is still awaiting approval. However, there is a large amount of equipment in stock, ready for immediate shipment. • We still haven't seen the expected AI boom. Lisa Su points to the MI350 ramp-up for this. The market and investors now want to see results. The second half of 2025 is critical.